Literature DB >> 15494623

Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators.

.   

Abstract

Adults with cognitive impairment are considered a vulnerable population. The conditions associated with cognitive impairment, such as dementia and delirium, cause great suffering to affected patients and their families. Improving clinical care for these conditions depends on research involving cognitively impaired participants. Cognitive impairment is at times associated with partial or full impairment of the capacity to consent to research. This both limits the ability of the individual to consent personally to research participation, and also increases pressure upon Institutional Review Boards (IRBs) and investigators to place additional safeguards for the appropriate participation of cognitively impaired individuals in research. While the ethical and legal principles permitting and safeguarding the participation of cognitively impaired persons in research are generally agreed upon, there are no specific methods that operationalize these principles in a language that can be used by IRBs and researchers to guide their day-to-day work in this area. This document contains recommendations that IRBs and investigators can use to operationalize the informed consent process for individuals with cognitive impairment. In situations in which IRBs might not have specific policies in this area, this guideline may also serve as the foundation for such policies. The recommendations discuss when to consider that cognitively impaired participants might be involved in a research project, the use of screening for cognitive impairment, the conduct of assessments evaluating capacity to consent to research, situations in which proxies might consent for research participation in the place of cognitively impaired participants, how to go about identifying appropriate proxies, and how to deal with the loss of consent capacity in the course of a research project.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  2004        PMID: 15494623     DOI: 10.1097/01.wad.0000137520.23370.56

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  36 in total

1.  Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease.

Authors:  Michelle M Mielke; Ozioma C Okonkwo; Kenichi Oishi; Susumu Mori; Sarah Tighe; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012       Impact factor: 21.566

2.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

3.  IL-6 release by LPS-stimulated peripheral blood mononuclear cells as a potential biomarker in Alzheimer's disease.

Authors:  Adam Kaplin; Katherine A L Carroll; Jenn Cheng; Rameeza Allie; Constantine G Lyketsos; Peter Calabresi; Paul B Rosenberg
Journal:  Int Psychogeriatr       Date:  2008-12-01       Impact factor: 3.878

4.  Research With Cognitively Impaired Participants.

Authors:  Ukamaka M Oruche
Journal:  J Nurs Law       Date:  2009-10-01

5.  Sertraline for the treatment of depression in Alzheimer disease.

Authors:  Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-02       Impact factor: 4.105

6.  Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

Authors:  Daniel Weintraub; Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-04       Impact factor: 4.105

7.  Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Authors:  Dean F Wong; Robert A Comley; Hiroto Kuwabara; Paul B Rosenberg; Susan M Resnick; Susanne Ostrowitzki; Cristina Vozzi; Frank Boess; Esther Oh; Constantine G Lyketsos; Michael Honer; Luca Gobbi; Gregory Klein; Noble George; Lorena Gapasin; Kelly Kitzmiller; Josh Roberts; Jeff Sevigny; Ayon Nandi; James Brasic; Chakradhar Mishra; Madhav Thambisetty; Abhay Mogekar; Anil Mathur; Marilyn Albert; Robert F Dannals; Edilio Borroni
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

8.  Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease.

Authors:  Milap A Nowrangi; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos; Kenichi Oishi; Marilyn Albert; Susumu Mori; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2012-12-12       Impact factor: 21.566

9.  The physical environment influences neuropsychiatric symptoms and other outcomes in assisted living residents.

Authors:  Mark C Bicket; Quincy M Samus; Mathew McNabney; Chiadi U Onyike; Lawrence S Mayer; Jason Brandt; Peter Rabins; Constantine Lyketsos; Adam Rosenblatt
Journal:  Int J Geriatr Psychiatry       Date:  2010-10       Impact factor: 3.485

10.  Predictors of providing informed consent or assent for research participation in assisted living residents.

Authors:  Betty S Black; Jason Brandt; Peter V Rabins; Quincy M Samus; Cynthia D Steele; Constantine G Lyketsos; Adam Rosenblatt
Journal:  Am J Geriatr Psychiatry       Date:  2008-01       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.